“Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s441. doi:10.25251/skin.8.supp.441.